Therapeutic insulins and their large-scale manufacture

@article{Walsh2004TherapeuticIA,
  title={Therapeutic insulins and their large-scale manufacture},
  author={Gary Walsh},
  journal={Applied Microbiology and Biotechnology},
  year={2004},
  volume={67},
  pages={151-159}
}
  • G. Walsh
  • Published 2004
  • Medicine
  • Applied Microbiology and Biotechnology
Biotechnological innovations over the past 25 years have underpinned the rapid development of a thriving biopharmaceutical sector. Therapeutic insulin remains one of the most commonly used products of pharmaceutical biotechnology and insulin-based products command annual global sales in excess of $4.5 billion. Innovations in its method of production and in particular the advent of engineered insulin analogues provide a fascinating insight into how scientific and technological advances have… Expand
Pursuit of a perfect insulin
TLDR
A broad set of drug candidates, targeting hyperglycaemia plus other disease abnormalities, is now progressing through the clinic, with initial prototypes now reaching the proof-of-concept stage and the first alternatives to injectable delivery have progressed to registration. Expand
Cell factories for insulin production
TLDR
This review would focus in this review, on various approaches that can be exploited to increase the production of a biologically active insulin and its analogues in E. coli and yeast. Expand
Current Applications of Pharmaceutical Biotechnology
The use of recombinant DNA methods to produce large quantities of protein for therapeutic uses has revolutionized medicine. Industrial challenges for manufacture of biotherapeutic proteins areExpand
Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy
TLDR
Patients with diabetes could be safely and effectively transferred from animal or semisynthetic human insulin to recombinant human insulin with no change expected in insulin dose, and follow-up after any change of insulin product is recommended to confirm clinical efficacy. Expand
Recent Challenges in Insulin Delivery Systems: A Review
TLDR
The inhalation delivery system Exubera® has already become clinically available in the United States and Europe for patients with diabetes as non-invasive delivery system. Expand
Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development
TLDR
This chapter introduces the various classes of therapeutics that are produced using recombinant DNA technology, and provides background on the history and evolution of therapeutic hormones, enzymes, cytokines, and monoclonal antibodies. Expand
Therapeutic agents comprising elastic peptides
The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptorExpand
Lessons learned from biosimilar epoetins and insulins
TLDR
Two case studies are discussed of three insulin formulations which were physicochemically similar to comparator insulins, but with pharmacokinetic and pharmacodynamic profiles sufficiently different to have potentially serious clinical consequences and that of Eprex, for which an apparently minor change in one formulation caused an upsurge in patients with diabetes and renal failure. Expand
New Peptide Based Therapeutic Approaches
A large number of chemically well defined and synthetic linear as well as branched therapeutics peptides have been developed and used for a large number of therapeutic applications. Peptides andExpand
Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems
TLDR
Key issues associated with the production and manufacturing of biosimilar insulins are reviewed, including a European regulatory perspective on manufacturing guidelines designed to ensure clinical efficacy and patient safety. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Insulin therapies - past, present and future.
TLDR
The next few years will see several novel approaches to mimic the endogenous release and kinetics of insulin, and also many improved analogues designed to achieve better control and effective treatment of diabetes. Expand
Monomeric insulins obtained by protein engineering and their medical implications
TLDR
It is reported that it is possible, by single amino-acid substitutions, to make insulins which are essentially monomeric at pharmaceutical concentrations and which have largely preserved their biological activity, capable of giving diabetic patients a more physiological plasma insulin profile at the time of meal consumption. Expand
Research, Development, Production, and Safety of Biosynthetic Human Insulin
TLDR
The daily treatment of more than two million diabetic patients worldwide with this rDNA human insulin not only demonstrates the value of rDNA technology in providing an important medical product, it is assurance that diabetic patients will have unlimited supplies of this vital hormone as well as potential analogue refinements. Expand
Monomeric Insulins and Their Experimental and Clinical Implications
TLDR
The development of a series of human insulin analogues with reduced tendency to selfassociation that, because of more rapid absorption, are better suited to meal-related therapy and have the potential to minimize late hypoglycemia. Expand
Insulins today and beyond
TLDR
Parallel developments in glucose-sensing technologies are welcomed as an integral part of safe and optimum implementation of insulin replacement therapy. Expand
Closed-loop insulin delivery-the path to physiological glucose control.
TLDR
Experimental closed-loop data employing intravenous and subcutaneous glucose sensors and implanted and external insulin pumps (Medtronic MiniMed, Northridge CA) are presented and algorithms are evaluated for their ability to deliver insulin. Expand
Insulin Lispro (Humalog)
TLDR
Insulin LISPRO (Humalog(R)) is such an analogue which has gained regulatory approval for general medical use and is identical to human insulin except that the Pro-Lys amino acid sequence at positions B28 and B29 of the native molecule are reversed. Expand
New Developments in Insulin Delivery
TLDR
The different routes available for insulin administration and the many successful developments that have been made in recent years for improving that particular route for a much better insulin delivery are reviewed. Expand
Alternative routes of insulin delivery
TLDR
If long‐term safety and efficacy is confirmed, inhalation may become the first non‐subcutaneous route of insulin administration for widespread clinical use, despite overwhelming interest and investment in administering insulin via the oral route. Expand
Oral insulin delivery.
TLDR
The use of permeation enhancers, protease inhibitors, enteric coatings and polymer microsphere formulations will be covered, including commentary on which methods hold more promise towards the successful development of oral insulin. Expand
...
1
2
3
4
5
...